Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

Details

Serval ID
serval:BIB_91E1362A1B81
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
Journal
Inflammatory Bowel Diseases
Author(s)
Feagan B.G., Lémann M., Befrits R., Connell W., D'Haens G., Ghosh S., Michetti P., Ochsenkühn T., Panaccione R., Schreiber S., Silverberg M., Sorrentino D., van der Woude C.J., Vermeire S., Rutgeerts P.
ISSN
1536-4844 (Electronic)
ISSN-L
1078-0998
Publication state
Published
Issued date
2012
Volume
18
Number
1
Pages
152-160
Language
english
Abstract
Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.
Pubmed
Web of science
Create date
09/02/2012 10:29
Last modification date
20/08/2019 14:55
Usage data